- Home
- BCAB vs FLYX Comparison
BCAB vs FLYX Comparison
Compare BCAB & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAB | FLYX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 79.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCAB | FLYX |
|---|---|---|
| Price | $0.66 | $3.13 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 14.9K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $362,955,000.00 |
| Revenue This Year | N/A | $28.47 |
| Revenue Next Year | N/A | $22.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.38 |
| 52 Week Low | $0.24 | $1.90 |
| 52 Week High | $1.43 | $6.90 |
Technical Indicators
Market Signals| Indicator | BCAB | FLYX |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 44.48 |
| Support Level | $0.74 | $3.08 |
| Resistance Level | $0.83 | $3.46 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 14.83 | 10.53 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.